NEW YORK ( TheStreet) -- Savient Pharmaceuticals (Nasdaq: SVNT) hit a new 52-week low Monday as it is currently trading at $2.26, below its previous 52-week low of $2.27 with 1.5 million shares traded as of 2:56 p.m. ET. Average volume has been 1.7 million shares over the past 30 days. Savient has a market cap of $168 million and is part of the health care sector and drugs industry. Shares are down 79.4% year to date as of the close of trading on Friday. Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company in the United States. It engages in developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients refractory to conventional therapy.
- Sign up for TheStreet's FREE Dividend and Income Investor Newsletter